PharmaDrug adds depth to its board with new Director who has a wealth of healthcare and addiction-therapy experience.
Psychedelics
Revive Therapeutics Expands Research Partnership for Novel Formulation Development and Clinical Research of Psilocybin with University of Wisconsin-Madison
Revive expands on its psychedelics research aimed at addiction treatment.
Champignon Announces Closing of $15 Million Bought Deal Private Placement
Champignon Brands closes on a $15 million financing to expand its clinical psychedelics research programs.
Numinus receives Health Canada licence amendment to produce and extract psilocybin from mushrooms
Numinus becomes the first publicly traded company in Canada to obtain such licensing for psychedelics research.
Will Compass Pathways Be The Next Unicorn?
As rumors swirl about Compass Pathways going public, this could become the first psychedelics Unicorn.
MindMed Begins Phase 2 Clinical Trial of LSD for Treating "Suicide Headaches"
MindMed begins a Phase 2 clinical trial of LSD for cluster headaches in Switzerland.
Champignon Identifies Synthetic Ketamine and Psilocybin/Psilicin Metabolite Targets; Selects Dalriada to Advance IP Portfolio
Champignon Brands has added a new contact research organization (CRO) to advance its IP portfolio.
Hollister Biosciences Inc. Subsidiary AlphaMind Brands Inc. Plans Launch of Initial Medicinal Mushroom Based Product Line
AlphaMind Brands Inc is entering the functional mushrooms market.
MindMed Launches Project Lucy Focused On LSD Experiential Therapy For Anxiety Disorders
MindMed has high hopes for its new LSD-based anxiety therapy.
Dr. Devon Christie, MD CCFP RTC IFMCP, joins Numinus as Medical Director
Numinus adds to its management team.
MindMed Further Expands Phase 2 Clinical Trial of Microdosing LSD For Adult ADHD
MindMed's Microdosing Division is expanding its ADHD clinical trial.
Champignon Announces Voluntary Share Lock-Up; Retains Gold Standard Media, LLC for Financial Marketing
Certain shareholders have agreed to a voluntary resale restriction that covers 17.8 million shares.
Numinus Announces 2020 Operational Plans to Scale
Newly-listed Numinus Wellness provides a corporate update.
Psychedelic Drug Therapy: Laying Out The Picture
Psychedelic drug proponents have touted some very exciting clinical studies. Investors will want to look past the headlines and take a closer look at these drug therapies.
MindMed Adds MDMA for Development of Next-Gen Psychedelic Therapies
MindMed further expands R&D collaboration with University Hospital Basel's Liechti Lab with plans to develop next-gen psychedelic therapies combining LSD and MDMA.